Comparative Pharmacology
Head-to-head clinical analysis: LINCOMYCIN HCL versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINCOMYCIN HCL versus LINCOMYCIN HYDROCHLORIDE.
LINCOMYCIN HCL vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic